Buz Investors PUBLIC SERVICES, IMPROVE PATIENT CARE The Manitoba government is introducing companion pieces of legislation to protect the front-line services relied upon by Manitoba families, deliver better patient care through necessary


Creation of Permanent Voter Registry, Proof of Identity Requirements Would Bring Manitoba In Line With Other Jurisdictions

Buz Investors Creation of Permanent Voter Registry Proposed changes to The Elections Amendment Act would create a permanent and regularly updated database of eligible voters for all future provincial elections, increasing the efficiency a

Buz Investors Creation of Permanent Voter Registry Proposed changes to The Elections Amendment Act would create a permanent and regularly updated database of eligible voters for all future provincial elections, increasing the efficiency and accuracy of Manitoba’s voter system while ensuring Elections Manitoba retains the ability and authority to verify the database with targeted outreach to voters, Justice Minister Heather Stefanson announced today.

“Manitoba is currently the only jurisdiction in Canada that does not have a register of voters,” said Stefanson.  “This legislation would establish a more accurate voters list and significantly reduce the need to enumerate Manitobans before every election.  This modernized approach would allow for better services to voters.”


Creation of Permanent Voter Registry

The new database would be based on the final voters list from the 2016 general election and would be regularly updated with information from federal, provincial and municipal sources, as well as through direct updates from voters.  In order to achieve a more complete list, information related to 16 and 17-year-old residents of Manitoba could be added to the register in recognition of the fact they may become eligible to vote within a few years, the minister noted.

Elections Manitoba would have the authority to carry out targeted registration programs before an election is called to ensure the database is as current as possible.  The registrar would also be required to be updated following the revision of electoral boundaries.

Once registered to vote, individuals would be assigned a unique identifier that would remain the same from election to election that would assist in distinguishing voters from one another.  The legislation would allow registered voters to remain on the permanent list without requiring them to register again for future elections, though voters could choose to contact Elections Manitoba to opt out of the database without affecting their right to vote.

Those in the database would receive an information card before election day that must indicate the address of the voter’s voting station, the voting hours on election day, and the dates, locations and hours of advance voting stations in the voter’s electoral division.

The legislation also would require voters to present proof of identity and address when they vote or to make a declaration about their address when voting.  Similar to the proof of identification requirements for municipal elections in Winnipeg and federal elections across Manitoba, a voter could present a wide range of documents to establish his or her identity.  In addition, the legislation would allow a voter who is on the voters list, but who cannot produce the necessary documentation to establish their identity, to vote if another resident of the same electoral division (with the required identification) were to vouch for them.

“Manitoba voters are required to show identification to vote in federal elections, during municipal elections in our province’s two largest cities, and when voting in advance polls during provincial elections,” said Stefanson.  “This legislation would ensure accessibility, consistency and predictability for voters while also improving upon the integrity of our democratic process.”

Other proposed changes in the act include:
• requiring schools to have an in-service on the day of a fixed-date general election in order to better protect the safety of children on election day when hundreds of adult strangers have access to the building;
• allowing a person who is not on the voter list to be added to the list on election day and permitted to vote after taking an oath and producing the required identification;
• permitting absentee voters to cast a ballot for a registered political party instead of a candidate, allowing them to vote before nominations close; and
• allowing the chief electoral officer to make changes to Manitoba’s voting processes after consulting with an all-party advisory committee established for this purpose, and the Standing Committee on Legislative Affairs would also have to approve any changes.

Ebates Coupons and Cash Back

Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )

Mylan Taking Immediate Action to Further Enhance Access to EpiPen

Mylan Taking Immediate Action to Further Enhance Access to EpiPen

Mylan Taking Immediate Action to Further Enhance Access to EpiPen

Mylan Taking Immediate Action to Further Enhance Access to EpiPen

Mylan doubling the eligibility for patient assistance, effectively eliminating out-of-pocket expense for uninsured and under-insured patients
Company to cover up to $300 of out-of-pocket cost at pharmacy; reducing patient cost by 50% off Mylan list price
Mylan also to open pathway to provide EpiPen® Auto-Injector directly to patients

HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced it is taking immediate action to further enhance access to EpiPen®(epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs. The company is reducing the patient cost of EpiPen® Auto-Injector through the use of a savings card which will cover up to $300 for their EpiPen 2-Pak®. For patients who were previously paying the full amount of the company’s list price for EpiPen®, this effectively reduces their out-of-pocket cost exposure by 50%. Mylan also is doubling the eligibility for its patient assistance program, which will eliminate out-of-pocket costs for uninsured and under-insured patients and families as well.

Mylan CEO Heather Bresch said, “We have been a long-term, committed partner to the allergy community and are taking immediate action to help ensure that everyone who needs an EpiPen® Auto-Injector gets one. We recognize the significant burden on patients from continued, rising insurance premiums and being forced increasingly to pay the full list price for medicines at the pharmacy counter. Patients deserve increased price transparency and affordable care, particularly as the system shifts significant costs to them. However, price is only one part of the problem that we are addressing with today’s actions. All involved must also take steps to help meaningfully address the U.S. healthcare crisis, and we are committed to do our part to drive change in collaboration with policymakers, payors, patients and healthcare professionals.”

Mylan has worked to help patients with commercial insurance pay as little as $0 for EpiPen® Auto-Injector using the My EpiPen Savings Card®. In 2015, this resulted in nearly 80% of these patients paying nothing out of pocket for their EpiPen® Auto-Injector. However, as the health insurance environment has evolved, driven by the implementation of the Affordable Care Act, patients and families enrolled in high deductible health insurance plans, who are uninsured, or who pay cash at the pharmacy, have faced higher costs for their medicine.

Mylan is taking the following immediate actions to help further address the needs of patients and families:

  • For patients in health plans who face higher out-of-pocket costs, the company is providing immediate relief by offering a savings card for up to $300. This will effectively reduce by 50% the cost exposure for patients who would have otherwise paid the full list price for EpiPen® Auto-Injector.
  • Mylan also is doubling eligibility for our patient assistance program to 400% of the federal poverty level. This means a family of four making up to $97,200 would pay nothing out of pocket for their EpiPen® Auto-Injector.
  • Further, Mylan will continue to offer the EpiPen4Schools® program. The program, launched inAugust 2012, has provided more than 700,000 free epinephrine auto-injectors and educational resources to more than 65,000 schools nationwide to help them be prepared for anaphylaxis events among students.
  • Mylan also is opening a pathway so that patients can order EpiPen® Auto-Injector directly from the company, thereby reducing the cost.

These programs will apply to EpiPen® and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors.

In the interest of fostering greater price transparency in the healthcare system, Mylan is providing the entire economic story of the EpiPen® supply chain on our website.


About EpiPen® (epinephrine injection, USP) Auto-Injector

EpiPen® (epinephrine injection, USP) and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors are used for the emergency treatment of life-threatening allergic reactions. Each EpiPen 2-Pak® and EpiPen Jr 2-Pak® contains two single auto-injectors, instructions for use and a training device, with no drug product or needle, to help patients become familiar with the administration technique. EpiPen® Auto-Injector should be administered immediately at the first sign of an anaphylactic reaction. EpiPen® Auto-Injector is not a substitute for emergency medical treatment. Patients should seek emergency medical attention immediately following administration. For more information about EpiPen® Auto-Injector, visit epipen.com.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 2,700 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in more than 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our more than 40,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com